Direkt zum Inhalt
Merck

Eph-B4 regulates adaptive venous remodeling to improve arteriovenous fistula patency.

Scientific reports (2017-11-15)
Clinton D Protack, Trenton R Foster, Takuya Hashimoto, Kota Yamamoto, Monica Y Lee, Jan R Kraehling, Hualong Bai, Haidi Hu, Toshihiko Isaji, Jeans M Santana, Mo Wang, William C Sessa, Alan Dardik
ZUSAMMENFASSUNG

Low rates of arteriovenous fistula (AVF) maturation prevent optimal fistula use for hemodialysis; however, the mechanism of venous remodeling in the fistula environment is not well understood. We hypothesized that the embryonic venous determinant Eph-B4 mediates AVF maturation. In human AVF and a mouse aortocaval fistula model, Eph-B4 protein expression increased in the fistula vein; expression of the arterial determinant Ephrin-B2 also increased. Stimulation of Eph-B-mediated signaling with Ephrin-B2/Fc showed improved fistula patency with less wall thickness. Mutagenesis studies showed that tyrosine-774 is critical for Eph-B4 signaling and administration of inactive Eph-B4-Y774F increased fistula wall thickness. Akt1 expression also increased in AVF; Akt1 knockout mice showed reduced fistula diameter and wall thickness. In Akt1 knockout mice, stimulation of Eph-B signaling with Ephrin-B2/Fc showed no effect on remodeling. These results show that AVF maturation is associated with acquisition of dual arteriovenous identity; increased Eph-B activity improves AVF patency. Inhibition of Akt1 function abolishes Eph-B-mediated venous remodeling suggesting that Eph-B4 regulates AVF venous adaptation through an Akt1-mediated mechanism.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-Phosphotyrosin-Antikörper, Klon 4G10®, clone 4G10®, Upstate®, from mouse
Sigma-Aldrich
NVP-BHG712, ≥98% (HPLC)